Omeros (OMER) Capital Leases (2017 - 2018)
Omeros recorded quarterly Capital Leases of $1.6 million in Q4 2018, up 94.81% quarter-over-quarter from $810000.0 in Q4 2017, and up 94.81% year-over-year from $810000.0 in Q4 2017.
Omeros' Capital Leases history runs 2 years deep, the most recent figure standing at $1.6 million for Q4 2018.
- In Q4 2018, Capital Leases rose 94.81% year-over-year to $1.6 million; the TTM figure through Dec 2018 stood at $1.6 million (up 94.81% YoY), while the FY2018 annual figure was $1.6 million, up 94.81% from the prior year.
- Capital Leases came in at $1.6 million for Q4 2018 at Omeros, up from $810000.0 in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $1.6 million in Q4 2018 to a low of $810000.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.58 Mn |
| Dec 31, 2017 | 810,000.00 |